8-K: Vycor Medical Reports Declining Q2 2026 Results

Vycor Medical, Inc. announced financial results for the three and six months ended June 30, 2026, showing a decrease in revenue and operating profit for its Vycor Medical division.

Summary

• Vycor Medical, Inc. reported financial results for the three and six months ended June 30, 2026.
• Total revenue for the three months decreased by 16% to $418,264, and for the six months decreased by 6% to $876,804 compared to the prior year periods.
• The Vycor Medical division (VBAS) saw revenue declines of 17% for the quarter and 7% for the six months, primarily attributed to international markets.
• Gross profit also decreased for both periods, with a 19% drop for the quarter and an 8% drop for the six months.
• Operating profit for the three months fell to $6,851 from $51,146 in the prior year, and for the six months it increased to $52,659 from $38,340.
• Non-GAAP operating profit showed a decrease for both periods, down to $22,952 for the quarter and $82,740 for the six months.
• The NovaVision division, still in development, showed revenue increases of 17% for the quarter and 8% for the six months.
• Three new peer-reviewed studies were published on the ViewSite Brain Access System (VBAS) during 2026, bringing the total to 53.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining revenues and operating profits, despite positive clinical study results for their VBAS system.

Positives

• Three new peer-reviewed studies were published on the ViewSite Brain Access System (VBAS) in 2026, highlighting its effectiveness in complex pediatric tumor cases and safer tumor resection compared to traditional methods.
• A retrospective study on minimally invasive suboccipital tubular resection using VBAS showed effective decompression of posterior fossa metastases with low cerebrospinal fluid diversion rates.
• The NovaVision division, in development, experienced revenue growth of 17% for the three months and 8% for the six months ended June 30, 2026.
• The Vycor Medical division's VBAS system has been validated through over 50 peer-reviewed studies, demonstrating benefits such as less brain tissue damage, less invasive procedures, improved access, and reduced operating/recovery time.
• The VBAS system is protected by 49 issued and 8 pending patents.

Negatives

• Revenue for the three months ended June 30, 2026, decreased by 16% to $418,264 compared to the prior year.
• Revenue for the six months ended June 30, 2026, decreased by 6% to $876,804 compared to the prior year.
• The Vycor Medical division's revenue decreased by 17% for the three months and 7% for the six months, primarily due to international market performance.
• Gross profit decreased by 19% for the three months and 8% for the six months.
• Operating profit for the three months ended June 30, 2026, was $6,851, a significant decrease from $51,146 in the prior year.
• Non-GAAP operating profit decreased to $22,952 for the three months and $82,740 for the six months, compared to $85,712 and $106,100 respectively in the prior year.
• Net loss available to common stockholders was ($22,288) for the three months and ($164,365) for the six months, compared to a net income of $23,887 and a net loss of ($176,861) in the prior year periods respectively.

Risks

• International sales can be unpredictable due to the lumpy nature of large orders.
• The NovaVision division requires significant development to address its market potential.
• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could cause actual results to differ materially.

Future Outlook

The filing does not contain specific forward-looking guidance. However, it mentions that the NovaVision division requires significant development to address its market potential.

Management Comments

• Management believes that non-GAAP financial measures provide investors with insight into what is used by management to conduct a more meaningful and consistent comparison of ongoing operating results and trends.
• Management believes that excluding non-cash depreciation and non-cash stock-based compensation allows for a more accurate comparison of financial results to previous periods and is useful for investors to understand the specific impact of these expenses.

Industry Context

StockSavvy.ai notes that the decline in Vycor Medical's revenue, particularly from international markets, is a concern in the medical device sector, which often experiences fluctuations. However, the continued positive clinical validation of the VBAS system in peer-reviewed studies is a strong counterpoint, suggesting potential for future growth if market penetration can be improved.

Related Party Transactions

• Interest expense related to a related party was ($12,570) for the three months ended June 30, 2026, and ($25,140) for the six months ended June 30, 2026.

Stakeholder Impact

• Shareholders may be concerned by the declining revenues and profits, despite positive clinical study outcomes.
• Employees may face uncertainty due to the revenue downturn.
• Customers (hospitals and surgeons) continue to benefit from the clinical validation of the VBAS system.
• Suppliers may experience reduced order volumes due to the revenue decrease.

Next Steps

• Continue to develop the NovaVision division to address its market potential.
• Leverage the positive clinical study results for the VBAS system to drive market penetration.

Key Dates

Recommendation

The company shows declining revenue and profitability, which is a negative. However, the strong clinical validation and patent protection for the VBAS system, along with growth in the NovaVision division, suggest underlying value. A 'hold' recommendation is appropriate given the mixed results, pending further clarity on international market performance and NovaVision's development.

Keywords

Vycor Medical, VBAS, NovaVision, Neurosurgery, Visual Rehabilitation, Financial Results, Medical Devices